Drug for thyroid eye disorder
Horizon Therapeutics has announced that its IGF-1R inhibitor Tepezza (teprotumumab-trbw) has become the first and only therapy approved by the FDA for the treatment of thyroid eye disease (TED).
The drug was reviewed under the US regulator’s Priority Review pathway and provides a new treatment to tackle the rare, progressive autoimmune disease which can, in some cases, lead to vision loss. The condition is characterised by bulging of the eyes, blurred or double vision, inflammation and pain.
